Medinice S.A (ICE) - Total Assets
Based on the latest financial reports, Medinice S.A (ICE) holds total assets worth zł92.73 Million PLN (≈ $25.52 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Medinice S.A cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Medinice S.A - Total Assets Trend (2016–2025)
This chart illustrates how Medinice S.A's total assets have evolved over time, based on quarterly financial data. See ICE total equity for net asset value and shareholders' equity analysis.
Medinice S.A - Asset Composition Analysis
Current Asset Composition (December 2025)
Medinice S.A's total assets of zł92.73 Million consist of 10.7% current assets and 89.3% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 10.4% |
| Accounts Receivable | zł2.00K | 0.0% |
| Inventory | zł0.00 | 0.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł34.24 Million | 36.9% |
| Goodwill | zł47.75 Million | 51.5% |
Asset Composition Trend (2016–2025)
This chart illustrates how Medinice S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ICE market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medinice S.A's current assets represent 10.7% of total assets in 2025, a decrease from 60.8% in 2016.
- Cash Position: Cash and equivalents constituted 10.4% of total assets in 2025, up from 0.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 87.0% of total assets, an increase from 37.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 51.5% of total assets.
Medinice S.A Competitors by Total Assets
Key competitors of Medinice S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
Sweden | Skr537.34 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
Medinice S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.87 | 4.00 | 10.82 |
| Quick Ratio | 6.87 | 4.00 | 10.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł8.50 Million | zł7.38 Million | zł11.71 Million |
Medinice S.A - Advanced Valuation Insights
This section examines the relationship between Medinice S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.40 |
| Latest Market Cap to Assets Ratio | 2.20 |
| Asset Growth Rate (YoY) | 7.1% |
| Total Assets | zł92.73 Million |
| Market Capitalization | $203.95 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Medinice S.A's assets at a significant premium (2.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Medinice S.A's assets grew by 7.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medinice S.A (2016–2025)
The table below shows the annual total assets of Medinice S.A from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł92.73 Million ≈ $25.52 Million |
+7.08% |
| 2024-12-31 | zł86.60 Million ≈ $23.83 Million |
+130.99% |
| 2023-12-31 | zł37.49 Million ≈ $10.32 Million |
-10.51% |
| 2022-12-31 | zł41.90 Million ≈ $11.53 Million |
-14.80% |
| 2021-12-31 | zł49.18 Million ≈ $13.53 Million |
+135.08% |
| 2020-12-31 | zł20.92 Million ≈ $5.76 Million |
+79.06% |
| 2019-12-31 | zł11.68 Million ≈ $3.22 Million |
+54.72% |
| 2018-12-31 | zł7.55 Million ≈ $2.08 Million |
+54.02% |
| 2017-12-31 | zł4.90 Million ≈ $1.35 Million |
+236.62% |
| 2016-12-31 | zł1.46 Million ≈ $400.82K |
-- |
About Medinice S.A
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technol… Read more